COAG · Hemab Therapeutics Holdings, Inc.
$49.61
+1.41 (+2.93%)
At close · Aug 21
Market Cap
$2.25B
Shares
46.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$48.20
Open$50.76
Day$46.57–51.69
Available close range$24.98–54.94
Avg vol 30d382K
Short int2.0M · 4.4% float · 4.3d
Short vol67%
Last earningsAug 11, 2026
DataMay 2026–Aug 2026
Filing10-Q · Aug 11
The closing range uses available history since May 1, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Limited
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
+17%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
78%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+55 funds added
Insider flow
Accumulating
Net +$1.7M over 90 days · 0% sells
Short interest
Rising
4.36% of float · ▲ +22.9% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
55 holders — 13F breadth
Squeeze score
69
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
98%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
8.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
+17%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
78%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+55 funds added
Insider flow
Accumulating
Net +$1.7M over 90 days · 0% sells
Short interest
Rising
4.36% of float · ▲ +22.9% MoM · 4.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
55 holders — 13F breadth
Price context
position in its available closing range
Range low $25
Now $48 · 78%
Range high $55
vs 50-day avg +17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COAG
this stock
Hemab Therapeutics Holdings, Inc.
|
$2.25B | — | — | — | 4.4% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COAG | -10.7% | +5.2% | — | +1.4% | — |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -8.7% | +1.9% | — | -0.7% | — |
Key facts
CIK
2114044
CUSIP
423494103
13F (30d)
61 filings
57 filers
Visit website
Investor relations